A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9

BACKGROUND: The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9. METHODS: H7 hemagglutinin (HA)-specific B cells were isolated from peripheral blo...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jingxin, Zhang, Li, Bao, Linlin, Wang, Yuxiao, Qiu, Lin, Hu, Jialei, Tang, Rong, Yu, Huiyan, Shan, Jun, Li, Yan, Qin, Chuan, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276153/
https://www.ncbi.nlm.nih.gov/pubmed/35671181
http://dx.doi.org/10.1097/CM9.0000000000002001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276153/
https://www.ncbi.nlm.nih.gov/pubmed/35671181
http://dx.doi.org/10.1097/CM9.0000000000002001

Ejemplares similares